DK1096937T3 - Ranolazinformuleringer med langvarig frigivelse - Google Patents

Ranolazinformuleringer med langvarig frigivelse

Info

Publication number
DK1096937T3
DK1096937T3 DK99948196T DK99948196T DK1096937T3 DK 1096937 T3 DK1096937 T3 DK 1096937T3 DK 99948196 T DK99948196 T DK 99948196T DK 99948196 T DK99948196 T DK 99948196T DK 1096937 T3 DK1096937 T3 DK 1096937T3
Authority
DK
Denmark
Prior art keywords
sustained release
release formulations
ranolazine sustained
ranolazine
formulations
Prior art date
Application number
DK99948196T
Other languages
Danish (da)
English (en)
Inventor
Andrew A Wolff
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26796494&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1096937(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Application granted granted Critical
Publication of DK1096937T3 publication Critical patent/DK1096937T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
DK99948196T 1998-09-10 1999-09-09 Ranolazinformuleringer med langvarig frigivelse DK1096937T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9980498P 1998-09-10 1998-09-10
US09/321,522 US6303607B1 (en) 1998-09-10 1999-05-27 Method for administering a sustained release ranolanolazine formulation
PCT/US1999/020968 WO2000013687A2 (en) 1998-09-10 1999-09-09 Sustained release ranolazine formulations
EP99948196A EP1096937B9 (en) 1998-09-10 1999-09-09 Sustained release ranolazine formulations

Publications (1)

Publication Number Publication Date
DK1096937T3 true DK1096937T3 (da) 2005-05-09

Family

ID=26796494

Family Applications (2)

Application Number Title Priority Date Filing Date
DK99948196T DK1096937T3 (da) 1998-09-10 1999-09-09 Ranolazinformuleringer med langvarig frigivelse
DK99968627T DK1109558T3 (da) 1998-09-10 1999-09-09 Ranolazinformuleringer med langvarig frigivelse

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK99968627T DK1109558T3 (da) 1998-09-10 1999-09-09 Ranolazinformuleringer med langvarig frigivelse

Country Status (33)

Country Link
US (14) US6303607B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (3) EP1109558B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (2) JP3745621B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100475759B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (2) CN1193757C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (3) AR022085A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (2) ATE217794T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (4) AU760435B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (2) BR9913626A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (2) CA2342390C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (1) CY2008020I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (2) CZ301375B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (3) DE69901570T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (2) DK1096937T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (2) ES2234302T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR09C0001I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GE (1) GEP20053420B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HK (1) HK1044284B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (2) HU224215B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (6) IL141892A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LU91504I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (2) MXPA01002599A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL300371I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (4) NO319434B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (2) NZ510384A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (3) PL202207B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (2) PT1096937E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (2) RU2214233C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (2) SI1096937T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TR (2) TR200101261T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TWI241911B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (2) UA75027C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (2) WO2000013687A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
JP2004505886A (ja) 2000-02-18 2004-02-26 スィーヴィー　セラピューティクス　インコーポレイテッド 鬱血性心不全の処置における部分的な脂肪酸酸化阻害剤
US20020052377A1 (en) * 2000-07-21 2002-05-02 Wolff Andrew A. Method for treating angina
WO2002032427A1 (en) * 2000-10-20 2002-04-25 Galephar M/F Stable oral formulation containing benzimidazole derivative
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
US20080109040A1 (en) * 2002-04-04 2008-05-08 Luiz Belardinelli Method of treating arrhythmias
BRPI0309142C1 (pt) 2002-04-09 2021-05-25 Flamel Ireland Ltd suspensão de microcápsulas em uma fase líquida aquosa, que permite a liberação modificada de pelo menos um princípio ativo com exclusão da amoxicilina e que é destinada a ser administrada por via oral
KR20050005437A (ko) * 2002-04-09 2005-01-13 플라멜 테크놀로지스 아목시실린의 변형 방출을 위한 마이크로캡슐 수성 현탁액형태의 경구 제약학적 제제
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
JP4546824B2 (ja) 2002-05-21 2010-09-22 ギリアード・パロ・アルト・インコーポレイテッド 糖尿病を処置する方法
GB0403098D0 (en) 2004-02-12 2004-03-17 Euro Celtique Sa Extrusion
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
KR20070093988A (ko) * 2005-01-06 2007-09-19 씨브이 쎄러퓨틱스, 인코포레이티드 라놀라진 함유 서방성 약제학적 제형물
FR2886150B1 (fr) * 2005-05-24 2007-08-24 Flamel Technologies Sa Forme pharmaceutique orale a base d'au moins un principe actif dont la solubilite varie en fonction des conditions de ph gastrique
WO2007016350A2 (en) * 2005-07-28 2007-02-08 Supernus Pharmaceuticals, Inc. Modified release tablet formulations with enhanced mechanical properties
WO2007108362A1 (ja) * 2006-03-17 2007-09-27 Konica Minolta Holdings, Inc. 有機エレクトロルミネッセンス素子、表示装置および照明装置
FI20060501L (fi) * 2006-05-22 2007-11-23 Biohit Oyj Koostumus ja menetelmä asetaldehydin sitomiseksi vatsassa
JP2010518171A (ja) * 2007-02-13 2010-05-27 ギリアード・パロ・アルト・インコーポレイテッド 非冠微小血管疾患の処置のためのラノラジンの使用
CA2678515A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of cardiovascular diseases
CA2678319A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of coronary microvascular diseases
US20090312340A1 (en) * 2007-02-13 2009-12-17 Whedy Wang Use of ranolazine for the treatment of cardiovascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
WO2008109175A1 (en) * 2007-03-07 2008-09-12 Concert Pharmaceuticals, Inc. Deuterated piperazine derivatives as anti-anginal compounds
US20080233191A1 (en) * 2007-03-22 2008-09-25 Brent Blackburn Use of ranolazine for elevated brain-type natriuretic peptide
RU2442585C2 (ru) * 2007-05-31 2012-02-20 Си Ви Терапьютикс, Инк. Способ лечения диабета
EP2170333B1 (en) * 2007-05-31 2013-02-20 Gilead Sciences, Inc. Ranolazine for elevated brain-type natriuretic peptide
CN101066253B (zh) * 2007-06-07 2011-01-05 北京本草天源药物研究院 一种雷诺嗪缓释片
WO2008157240A1 (en) * 2007-06-13 2008-12-24 Auspex Pharmaceuticals, Inc. Substituted piperazines
US20090012103A1 (en) * 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
US20090076018A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched ranolazine
EA201070914A1 (ru) * 2008-02-06 2011-04-29 Гайлид Сайэнсиз, Инк. Применение ранолазина для лечения боли
MX2011012140A (es) * 2009-05-14 2012-02-28 Gilead Sciences Inc Ranolazina para el tratamiento de problemas del snc.
EP2515880B1 (en) 2009-05-28 2019-11-27 Lupin Limited Novel pharmaceutical compositions of ranolazine
MX2012003362A (es) * 2009-09-25 2012-06-27 Lupin Ltd Composicion de liberación sostenida de ranolazina.
TWI508726B (zh) 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
TW201215392A (en) 2010-06-16 2012-04-16 Gilead Sciences Inc Use of ranolazine for treating pulmonary hypertension
ES2414384T3 (es) 2011-05-11 2013-07-19 Ratiopharm Gmbh Composición de liberación modificada que comprende ranolazina
NO3175985T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2011-07-01 2018-04-28
US20140221286A1 (en) 2011-09-21 2014-08-07 Gilead Sciences, Inc. Sodium channel blockers reduce glucagon secretion
US20160305924A1 (en) * 2013-04-26 2016-10-20 Laguna Pharmaceuticals , Inc. Methods for calibrating the administration of vanoxerine for terminating acute episodes of cardiac arrhythmia, restoring normal sinus rhythm, preventing recurrence of cardiac arrhythmia and maintaining normal sinus rhythm in mammals
CN104758265B (zh) * 2014-01-07 2019-05-17 四川海思科制药有限公司 一种雷诺嗪缓释片药物组合物及其制备方法
TW201618783A (zh) 2014-08-07 2016-06-01 艾森塔製藥公司 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
TW201717919A (zh) 2015-07-02 2017-06-01 國際藥品股份公司 雷諾多重壓縮錠劑
WO2018001582A1 (en) 2016-06-30 2018-01-04 Interquim, S.A. Ranolazine multiple compressed tablets
AR110252A1 (es) 2016-11-30 2019-03-13 Gilead Sciences Inc Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam
US10898444B2 (en) 2017-06-01 2021-01-26 Sun Pharmaceutical Industries Limited Extended release multiparticulates of ranolazine
CN112438955A (zh) * 2019-08-30 2021-03-05 深圳翰宇药业股份有限公司 一种雷诺嗪缓释组合物及其制备方法
JP2023507626A (ja) 2019-12-16 2023-02-24 テナックス・セラピューティクス，インコーポレイテッド 駆出率が保たれた心不全を伴う肺高血圧症（ＰＨ－ＨＦ－ｐＥＦ）を治療するためのレボシメンダン
CN110898024A (zh) * 2019-12-17 2020-03-24 卓和药业集团有限公司 一种治疗心绞痛的药物组合物及制备方法
GR1010345B (el) * 2021-12-16 2022-11-28 Φαρματεν Α.Β.Ε.Ε., Δισκια παρατεταμενης αποδεσμευσης που περιλαμβανουν ρανολαζινη και μεθοδος παραγωγης αυτων
WO2023130028A1 (en) 2021-12-31 2023-07-06 Tenax Therapeutics, Inc. Oral formulations of levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction
GR1010510B (el) * 2022-06-07 2023-07-20 Ελπεν Α.Ε. Φαρμακευτικη Βιομηχανια, Στερεες φαρμακοτεχνικες μορφες παρατεταμενης αποδεσμευσης ρανολαζινης

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
IL81419A0 (en) * 1986-01-30 1987-08-31 Syntex Inc Long acting sustained release pharmaceutical compositions containing dihydropyridines and their preparation
CA2019580C (en) * 1989-06-23 2007-03-27 Robert J. Dow Novel methods of treatment using ranolazine and related piperazine derivatives
US5527545A (en) 1989-09-18 1996-06-18 Recordati S.A. Chemical And Pharmaceutical Company Liquid-suspension controlled-release pharmaceutical composition
US5209933A (en) * 1990-01-10 1993-05-11 Syntex (U.S.A.) Inc. Long acting calcium channel blocker composition
JP2516524B2 (ja) * 1992-04-27 1996-07-24 大洋薬品工業株式会社 持続性製剤
JPH06199657A (ja) * 1992-12-10 1994-07-19 Sumitomo Pharmaceut Co Ltd 徐放性製剤
US5455045A (en) 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
JPH07112932A (ja) * 1993-08-27 1995-05-02 Mitsui Toatsu Chem Inc 徐放性医薬製剤
US5525606A (en) * 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
JPH08259446A (ja) * 1995-01-24 1996-10-08 Mitsui Toatsu Chem Inc 持効性医薬製剤
JPH08310946A (ja) * 1995-05-19 1996-11-26 Yuutoku Yakuhin Kogyo Kk 経皮吸収製剤
JPH09188617A (ja) * 1996-01-08 1997-07-22 Pola Chem Ind Inc 徐放性医薬組成物
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation

Also Published As

Publication number Publication date
NZ510384A (en) 2002-10-25
EP1109558B1 (en) 2002-05-22
CA2343376A1 (en) 2000-03-16
MXPA01002598A (es) 2002-04-08
NO20011191D0 (no) 2001-03-08
JP2002524416A (ja) 2002-08-06
NO20054324L (no) 2001-04-30
TWI241911B (en) 2005-10-21
NL300371I2 (nl) 2009-10-01
LU91504I2 (fr) 2009-02-03
EP1096937B1 (en) 2004-12-29
CZ301375B6 (cs) 2010-02-03
US6617328B2 (en) 2003-09-09
NO2009005I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2010-06-28
US6525057B2 (en) 2003-02-25
DE69901570D1 (de) 2002-06-27
HK1040060A1 (en) 2002-05-24
AU6036499A (en) 2000-03-27
CZ301341B6 (cs) 2010-01-20
US20030100566A1 (en) 2003-05-29
PL196668B1 (pl) 2008-01-31
GEP20053420B (en) 2005-01-25
NO20011192D0 (no) 2001-03-08
US20020090396A1 (en) 2002-07-11
IL141893A0 (en) 2002-03-10
PT1096937E (pt) 2005-04-29
IL175371A0 (en) 2006-09-05
PL348249A1 (en) 2002-05-20
US6864258B2 (en) 2005-03-08
IL141892A (en) 2006-08-20
AR053440A2 (es) 2007-05-09
DE69901570T2 (de) 2003-01-09
RU2214233C2 (ru) 2003-10-20
NO20011192L (no) 2001-04-30
US20040097514A1 (en) 2004-05-20
UA75027C2 (uk) 2006-03-15
US20050059667A1 (en) 2005-03-17
DE69922964D1 (de) 2005-02-03
AU6142599A (en) 2000-03-27
CZ2001879A3 (cs) 2001-08-15
AR022085A1 (es) 2002-09-04
TR200101261T2 (tr) 2002-05-21
HK1044284A1 (en) 2002-10-18
HK1044284B (zh) 2005-07-15
CN1193757C (zh) 2005-03-23
AR052921A1 (es) 2007-04-11
JP2006096757A (ja) 2006-04-13
CN1211086C (zh) 2005-07-20
US6503911B2 (en) 2003-01-07
CY2008020I2 (el) 2010-07-28
CN1354665A (zh) 2002-06-19
IL141893A (en) 2008-08-07
NO320986B1 (no) 2006-02-20
DE69922964T2 (de) 2005-12-08
UA67793C2 (uk) 2004-07-15
NO20011191L (no) 2001-04-30
US6303607B1 (en) 2001-10-16
ATE285774T1 (de) 2005-01-15
KR100475759B1 (ko) 2005-03-10
CA2342390A1 (en) 2000-03-16
HUP0104088A3 (en) 2002-12-28
FR09C0001I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2009-12-18
WO2000013686A2 (en) 2000-03-16
NO2009005I1 (no) 2009-03-16
PL202207B1 (pl) 2009-06-30
EP1109558A2 (en) 2001-06-27
CA2343376C (en) 2007-01-09
AU744071B2 (en) 2002-02-14
US20060147521A1 (en) 2006-07-06
US20050153982A1 (en) 2005-07-14
WO2000013687A2 (en) 2000-03-16
US20030099705A1 (en) 2003-05-29
DE122008000065I1 (de) 2009-04-09
PL196263B1 (pl) 2007-12-31
ES2177346T3 (es) 2002-12-01
WO2000013687A3 (en) 2000-06-29
BR9913553A (pt) 2001-10-23
US20060217397A1 (en) 2006-09-28
CA2342390C (en) 2006-08-29
ATE217794T1 (de) 2002-06-15
NL300371I1 (nl) 2009-02-02
BR9913626A (pt) 2001-12-04
RU2207856C2 (ru) 2003-07-10
AU2008207707A1 (en) 2008-09-25
EP1096937A2 (en) 2001-05-09
US6562826B1 (en) 2003-05-13
MXPA01002599A (es) 2005-02-17
US6620814B2 (en) 2003-09-16
FR09C0001I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2009-02-27
EP1527779A1 (en) 2005-05-04
WO2000013686A3 (en) 2000-07-06
US6852724B2 (en) 2005-02-08
IL180864A0 (en) 2007-07-04
IL141892A0 (en) 2002-03-10
ES2234302T3 (es) 2005-06-16
TR200101262T2 (tr) 2001-12-21
KR20010089874A (ko) 2001-10-12
NO319434B1 (no) 2005-08-15
HUP0103844A2 (hu) 2002-04-29
PT1109558E (pt) 2002-10-31
SI1096937T1 (en) 2005-04-30
US20020004506A1 (en) 2002-01-10
CY2008020I1 (el) 2010-07-28
US6369062B1 (en) 2002-04-09
AU760435B2 (en) 2003-05-15
HUP0103844A3 (en) 2002-11-28
NZ510386A (en) 2003-08-29
CN1321088A (zh) 2001-11-07
US20030166659A1 (en) 2003-09-04
HU224215B1 (hu) 2005-06-28
DK1109558T3 (da) 2002-08-26
SI1109558T1 (en) 2002-10-31
HUP0104088A2 (hu) 2002-05-29
US20040029890A1 (en) 2004-02-12
JP3745621B2 (ja) 2006-02-15
EP1096937B9 (en) 2007-02-28
PL347073A1 (en) 2002-03-11
CZ2001880A3 (cs) 2001-08-15
AU2008207703A1 (en) 2008-09-25
LU91504I9 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2019-01-02

Similar Documents

Publication Publication Date Title
DK1109558T3 (da) Ranolazinformuleringer med langvarig frigivelse
IS5555A (is) Selekoxib lyfjablöndur
ID30031A (id) Formulasi-formulasi agrokimia
ID23546A (id) Formulasi-formulasi ziprasidon
NO20004240D0 (no) Formuleringer
ATE224703T1 (de) Brauseformulierungen
NO20024270D0 (no) Vedvarende frigivelsesranolazinformuleringer
PT1130966E (pt) Formulacoes antiparasitarias
FI973816A0 (fi) Polypropen med hoeg smaeltstyrka
DE69805443D1 (de) Sachet-formulierungen
MA24473A1 (fr) Formulations
DK1109449T3 (da) Mikrokapselformuleringer
EP1083926A4 (en) VACCINE
ATE259590T1 (de) Pour-on formulierungen
NO20002126L (no) Formulering med forlenget frigjøring
IS6398A (is) Lyfjablöndur
ATE232683T1 (de) Mikrokapsel-formulierungen
IS5694A (is) Bóluefni
ATE268116T1 (de) Mesotrion-formulierungen
FI980856A0 (fi) Andningsskydd utrustad med en identifierare
NO982244D0 (no) Skumformuleringer
FI980596A0 (fi) Koerljussystem med blaendskyddsanordning